

Safety Alert

March 2024

Voriconazole– Interaction of Voriconazole with Flucloxacillin

EDA performs label update to include the following:

4.5 Interaction with other medicinal products and other forms of interaction

Medicinal Product	Interaction geometric mean changes	Recommendations concerning coadministration
Flucloxacillin (CYP450 inducer)	Significantly decreased plasma voriconazole concentrations have been reported	If concomitant administration of voriconazole with flucloxacillin cannot be avoided, monitor for potential loss of voriconazole effectiveness, increasing the dose of

Background:

Voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:

Treatment of invasive aspergillosis.

Treatment of candidaemia in non-neutropenic patients.

Treatment of fluconazole-resistant serious invasive *Candida* infections (including *C. krusei*).

Treatment of serious fungal infections caused by *Scedosporium* spp. and *Fusarium* spp.

Voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections.

Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.

References:

TGA ([Click here](#))